Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study
Basic & Clinical Pharmacology & Toxicology · 2026-12 · 139 (6)
DOI: 10.1111/bcpt.70329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 05.11.2026. Verfasst von Franck Maizaud und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France. Hauptthemen laut MEDLINE: Valganciclovir, Antiviral Agents, Cytomegalovirus Infections, Ganciclovir. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ganciclovir (GCV) exposure after standard valganciclovir (VGCV) prophylaxis is highly variable. Guidelines recommend Cockcroft–Gault for renal dose adjustment. We evaluated whether Cockcroft–Gault‐based dosing achieves the target prophylactic exposure (AUC 0‐24h: 40–60 mg.h/L) and whether MDRD or CKD‐EPI alters exposure.
Methods
Using a validated population pharmacokinetic model, we simulated 10 000 adult solid organ transplant recipients. VGCV doses were assigned according to SmPC renal function categories based on Cockcroft–Gault, MDRD or CKD‐EPI. Patient reclassification, target attainment and exposure around dosing thresholds (25, 40 and 60 mL/min) were assessed.
Results
MDRD and CKD‐EPI reclassified 45.1% and 39.9% of patients, mostly downward, lowering target attainment (20.1% and 22.7% vs. 30.8% with Cockcroft–Gault). Target attainment never exceeded 40% in any category, and underexposure predominated, reaching up to 94.1% in the most impaired renal function categories. Target attainment was consistently lower just below each threshold, and the 25 and 40 mL/min thresholds were set above the renal function ranges where the corresponding regimens achieved target exposure.
Conclusions
Renal function category‐based VGCV dosing does not reliably achieve target GCV exposure. Current thresholds are poorly aligned with the exposure‐response relationship and warrant re‐examination. Alternative equations do not reduce the variability, supporting exposure‐guided approaches such as therapeutic drug monitoring and model‐informed precision dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.
- INSERM UMR-1248 "Pharmacology & Transplantation", Limoges, France.
- University Hospital Federation "Survival Optimization in Organ Transplantation" (FHU SUPORT), Limoges, France.
- Institute of Pharmacy, CHU Lille, Lille, France.
- Department of Gastroenterology, CHU Lille, Lille, France.
- METRICS Research Laboratory (ULR 2694), Lille University, Lille, France.
ORCID-Profile: Franck Maizaud, Marc Labriffe, Stéphanie Belaiche, Pierre Marquet, Jean-Baptiste Woillard, Caroline Monchaud
Zitieren
APA
Maizaud, F., Labriffe, M., Sayadi, H., Belaiche, S., Marquet, P., Woillard, J. B., & Monchaud, C. (2026). Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study. Basic & Clinical Pharmacology & Toxicology, 139(6). https://doi.org/10.1111/bcpt.70329
Vancouver
Maizaud F, Labriffe M, Sayadi H, Belaiche S, Marquet P, Woillard JB, et al. Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study. Basic & Clinical Pharmacology & Toxicology. 2026;139(6). doi:10.1111/bcpt.70329
BibTeX
@article{Maizaud2026,
author = {Maizaud, Franck and Labriffe, Marc and Sayadi, Hamza and Belaiche, Stéphanie and Marquet, Pierre and Woillard, Jean-Baptiste and Monchaud, Caroline},
title = {Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {139},
number = {6},
doi = {10.1111/bcpt.70329}
}
EUVIMED